Sign in →

Test ID MFRGP Marfan Syndrome and Related Disorders Multi-Gene Panel, Blood

Useful For

Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of Marfan syndrome, Loeys-Dietz syndrome, thoracic aortic aneurysm and dissections, or a related disorder

 

Second-tier testing for patients in whom previous targeted gene variant analyses for specific Marfan and related genes were negative

 

Establishing a diagnosis of a Marfan or a related disorder in some cases, allowing for appropriate management and surveillance for aneurysms and other disease features based on the gene involved

 

Identifying variants within genes known to be associated with increased risk for aneurysms and other disease features allowing for predictive testing of at-risk family members

Method Name

Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Supplemental Sanger Sequencing

Reporting Name

Marfan and Related Genetic Panel, B

Specimen Type

Whole Blood EDTA

Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube.

Additional Information:

1. Include physician name and phone number with the specimen.

2. Prior Authorization is available for this test. Submit the required form with the specimen.

Forms:

1. Marfan and Related Disorders Patient Information (T636) in Special Instructions

2. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (T576) is available in Special Instructions.

3. Marfan Syndrome and Related Disorders Multi-Gene Panel Prior Authorization Ordering Instructions in Special Instructions

4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).

Specimen Minimum Volume

0.6 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole Blood EDTA Ambient (preferred)
  Refrigerated 

Clinical Information

Marfan syndrome (MFS) is an autosomal dominant genetic disorder affecting the connective tissue that occurs in approximately 1 to 2 per 10,000 individuals. It is characterized by the presence of skeletal, ocular, and cardiovascular manifestations and is caused by variants in the FBN1 gene. Skeletal findings may include tall stature, chest wall deformity, scoliosis, and joint hypermobility. Lens dislocation (ectopia lentis) is the cardinal ocular feature, and mitral valve prolapse and aortic root dilatation/dissection are the main cardiovascular features. Diagnosis is based on the revised Ghent nosology and genetic testing of FBN1. Management aims to monitor and slow the rate of aortic root dilatation, and initiate appropriate medical and/or surgical intervention as needed. Other phenotypes associated with the FBN1 gene include autosomal dominant ectopia lentis (displacement of the lens of the eye), thoracic aortic aneurysm and dissections (TAAD), isolated skeletal features of MFS, MASS phenotype (mitral valve prolapse, aortic diameter increased, stretch marks, skeletal features of MFS), Shprintzen-Goldberg syndrome (Marfanoid-craniosynostosis; premature ossification and closure of sutures of the skull), and autosomal dominant Weill-Marchesani syndrome (short stature, short fingers, ectopia lentis).

 

Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disease with significant overlap with Marfan syndrome, but may include involvement of other organ systems and is primarily caused by variants in TGFBR1 and TGFBR2. Features of LDS that are not typical of MFS include craniofacial and neurodevelopmental abnormalities, and arterial tortuosity with increased risk for aneurysm and dissection throughout the arterial tree. Variants of the SMAD3 gene have been reported in families with a LDS-like phenotype with arterial aneurysms and tortuosity and early onset osteoarthritis.

 

TAAD is a genetic condition primarily involving dilatation and dissection of the thoracic aorta, but may also include aneurysm and dissection of other arteries. TAAD has a highly variable age of onset and presentation, and may involve additional features such as congenital heart defects and other features of connective tissue disease or smooth muscle abnormalities depending on the causative gene. The gene most commonly involved in familial TAAD is ACTA2, followed by TGFBR1 and TGFBR2, and MYH11. Variants in the MYLK gene have been reported in a small subset of families with familial TAAD. TGFB2 variants have also been reported in families with TAAD and systemic features that overlap with LDS and MFS.

 

The COL3A1 gene causes Ehlers Danlos syndrome type IV (vascular type), an autosomal dominant connective tissue disease with characteristic facial features, thin, translucent skin, easy bruising, and arterial, intestinal, and uterine fragility. Arterial rupture may be preceded by aneurysm or dissection, or may occur spontaneously.

 

Autosomal dominant variants of the FBN2 gene are known to cause congenital contractural arachnodactyly (CCA), which has several overlapping features with Marfan syndrome, including dolichostenomelia, scoliosis, pectus deformity, arachnodactyly, and a risk for thoracic aortic aneurysm.

 

Variants of the CBS gene cause homocystinuria an autosomal recessive disorder of amino acid metabolism with clinical overlap with Marfan syndrome; including lens dislocation and skeletal abnormalities, as well as increased risk for abnormal blood clotting.

 

Mutations in the SKI gene cause Shprintzen-Goldberg syndrome (SGS), an autosomal dominant condition with overlap with LDS and MFS. Distinguishing features of SGS include hypotonia and intellectual disability. Aortic root dilatation is less frequent in SGS than in LDS or MFS, but, when present, it can be severe.

 

Homozygous and compound heterozygous loss of function variants in the SLC2A10 gene have been described in arterial tortuosity syndrome, a condition characterized by generalized tortuosity and elongation of all major arteries in addition to other connective tissue disease features.

 

Genes included in Marfan Syndrome and Related Disorders Multi-Gene Panel:

Gene

Protein

Inheritance

Known Association

ACTA2

Actin, alpha-2, smooth muscle, aorta

AD

TAAD

CBS

Cystathionine beta-synthase

AR

Homocystinuria

COL3A1

Collagen, type III, alpha-1

AD

Ehlers-Danlos syndrome Type IV (vascular type)

FBN1

Fibrillin 1

AD

Marfan syndrome/TAAD/Ectopia Lentis/ MASS phenotype/Shprintzen-Goldberg syndrome/Weill-Marchesani syndrome

FBN2

Fibrillin 2

AD

Congenital Contractural Arachnodactyly

MYH11

Myosin, heavy chain 11, smooth muscle

AD

TAAD

MYLK

Myosin light chain kinase

AD

TAAD

SKI

V-SKI avian sarcoma viral oncogene homolog

AD

Shprintzen-Goldberg syndrome

SLC2A10

Solute carrier family 2 (facilitated glucose transporter), member 10

AR

Arterial Tortuosity syndrome/TAAD (Autosomal Recessive)

SMAD3

Mothers against decapentaplegic, drosophila, homolog of, 3

AD

Loeys-Dietz syndrome/TAAD

TGFB2

Transforming growth factor, beta-2

AD

TAAD

TGFBR1

Transforming growth factor-beta receptor, type I

AD

Loeys-Dietz syndrome/TAAD

TGFBR2

Transforming growth factor-beta receptor, type II

AD

Loeys-Dietz syndrome/TAAD

Abbreviations: Autosomal dominant (AD), autosomal recessive (AR)

 

Indications for testing include but are not limited to:

-Patients who meet clinical diagnostic criteria (Revised Ghent nosology) for Marfan syndrome

-Patients in whom no specific Marfan or related disorder is evident but for whom there is a clear familial component

-Patients whose family history is consistent with TAAD

-Patients with a personal or family history of thoracic aortic aneurysm and/or dissection or a personal or family history of multiple arterial aneurysms

Reference Values

An interpretive report will be provided.

Cautions

Clinical Correlations:

Some individuals who have involvement of 1 or more of the genes on the panel may have a variant that is not identified by the methods performed (eg, promoter variants, deep intronic variants). The absence of a variant, therefore, does not eliminate the possibility of Marfan syndrome or a related disorder.

 

Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a family history of Marfan syndrome or a related disorder, it is often useful to first test an affected family member. Identification of a pathogenic variant in an affected individual would allow for more informative testing of at risk individuals.

 

Technical Limitations:

Next generation sequencing may not detect all types of genetic variants. Additionally, rare polymorphisms may be present that could lead to false negative or positive results. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. If the patient has had an allogeneic blood or marrow transplant or a recent (ie, less than 6 weeks from time of sample collection) heterologous blood transfusion these results may be inaccurate due to the presence of donor DNA.

 

Reclassification of Variants Policy:

At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

 

Contact the laboratory if additional information is required regarding the transcript and/or human genome assembly used for the analysis of this patient’s results.

Day(s) Performed

Wednesday; Varies

Report Available

4 weeks after prior authorization approved

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81410

NY State Approved

Conditional

Prior Authorization

Insurance preauthorization is available for this testing; forms are available in Special Instructions.

 

Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Medical Laboratories will receive information on eligibility and how to apply.